NUWE — Nuwellis, Inc.

Nuwellis Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.4 million, a 26% increase year-over-year from $1.9 million.
• Gross Margin: Improved to 70.1%, up 14% compared to the prior year, attributed to better pricing, product mix, and a shift to contract manufacturing.
• Operating Expenses: Increased to approximately $6 million from $4.1 million, driven by higher sales headcount and compensation.
• Net Loss: Approximately $4.3 million for the quarter.
• Cash Position: As of March 31, 2026, the company had $2.2 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Leadership Changes: Appointment of Carisa Schultz as CFO to enhance financial oversight and governance.
• Acquisition: Completed the acquisition of Rendiatech, which adds automated kidney function monitoring capabilities to Nuwellis' offerings.
• Pediatric Focus: Pediatrics now accounts for about 50% of U.S. revenue, with expansion to 47 centers, including six top children's hospitals.
• Sales Expansion: New territory established in South Texas, leveraging experienced sales personnel to boost growth in high-priority accounts.

3. Forward Guidance and Outlook

• The company aims to reduce monthly cash burn by approximately 50% by Q4 2026 while maintaining focus on areas with strong commercial traction.
• Continued emphasis on deepening utilization of Aquadex therapy and expanding clinical relevance in pediatrics and critical care.
• Anticipation of introducing the new Rendiatech product to the U.S. market in 2027.

4. Bad News, Challenges, or Points of Concern

• Despite revenue growth, the net loss of $4.3 million indicates ongoing financial challenges.
• Increased operating expenses could pressure margins if not managed effectively.
• The integration of Rendiatech is still in early stages, with no current market introduction, which may pose risks to timely execution of strategic goals.

5. Notable Q&A Insights

• Sales Strategy: The South Texas territory is seen as a significant opportunity due to the return of a top sales rep, with further growth expected in the Northeast and Western regions.
• Rendiatech Integration: The company has not yet introduced Rendiatech products to the market, focusing on developing a new product that will provide real-time kidney monitoring at the bedside, expected to launch in 2027.
• Aquadex Sales: The company sold 15 Aquadex units in Q1, including upgrades and new placements in both pediatric and adult accounts.

Overall, Nuwellis demonstrated strong revenue growth and strategic advancements in Q1 2026, while also facing challenges related to operating losses and the integration of new technologies. The company remains focused on executing its strategy and improving financial performance moving forward.